Virtual Facility Tour of discover@UTC

Featuring Poseida Therapeutics, Samumed and BMR

Complimentary Webinar for ISPE Members and $35 for Non-Members

Format:

GoToWebinar

Instructions to join will be emailed one day prior

Program Managers:

Nicki Lange, Director of Business Development, West Coast, G-CON Manufacturing Inc.
Dave Patterson, Account Manager, EMCOR Services, Mesa Energy Systems, Inc

Speakers:                 

  • Danielle Campbell, Senior Director of Operations, Poseida Therapeutics
  • Elizabeth Hawkins, LEED AP, DBIA, Operations Manager, Swinerton
  • Matt Masterson, Director of Leasing, BioMed Realty
  • Kat Stemmer, Associate Director of Facilities, Poseida Therapeutics

Overview:

Missing the days when you could tour the campuses of new life science companies? Well now you can…virtually! Join us for a virtual facility tour of BioMed Realty’s new discover@UTC campus where speakers Matt Masterson (BMR), Danielle Campbell (Poseida Therapeutics), Kat Stemmer (Poseida Therapeutics), and Elizabeth Hawkins (Swinerton) will highlight the new BMR campus and recent tenant improvement projects.

Missing the days when you could tour the campuses of new life science companies? Well now you can…virtually! Join us for a virtual facility tour of BioMed Realty’s new discover@UTC campus where speakers Matt Masterson (BMR), Danielle Campbell (Poseida Therapeutics), Kat Stemmer (Poseida Therapeutics), and Elizabeth Hawkins (Swinerton) will highlight the new BMR campus and recent tenant improvement projects.

Missing the days when you could tour the campuses of new life science companies? Well now you can…virtually! Join us for a virtual facility tour of BioMed Realty’s new discover@UTC campus where speakers Matt Masterson (BMR), Danielle Campbell (Poseida Therapeutics), Kat Stemmer (Poseida Therapeutics), and Elizabeth Hawkins (Swinerton) will highlight the new BMR campus and recent tenant improvement projects.

About The Featured Companies

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging proprietary next-generation, non-viral gene engineering technologies to create ground-breaking, life-saving cell and gene therapies for patients with high unmet medical needs. Established in 2015, Poseida Therapeutics uses broad gene engineering platform technologies to bring new and better treatments to patients with serious diseases like multiple myeloma, solid tumor cancers like prostate and breast cancer, and rare genetic diseases in the liver.

Poseida is advancing a wholly owned pipeline of product candidates based on their core proprietary technology platforms, including non-viral piggyBac DNA Modification System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies.

Poseida Therapeutics completed a crossover financing round just prior to an initial public offering in July 2020, going public on the Nasdaq under the ticker symbol PSTX.

Samumed is a leader in medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, Samumed develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The focus of Samumed’s technology platform is on the ability to modulate the Wnt pathway in select tissues with small molecules. To date, Samumed has discovered numerous new biological processes related to the Wnt pathway, identified novel biological targets, and developed small-molecule drugs that modulate Wnt activity. Samumed’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), SM08502 for numerous cancers, and a broad pipeline that ranges from neurology to degenerative disc disease.

BioMed Realty, a Blackstone portfolio company, is a leading provider of real estate solutions to the life science and technology industries. As of December 31, 2020, BioMed owns and operates high-quality life science real estate comprising 13.1 million square feet concentrated in leading innovation markets throughout the United States and United Kingdom, including Boston/Cambridge, San Francisco, San Diego, Seattle and Cambridge, U.K. In addition, BioMed maintains a premier development platform with 3.0 million square feet of Class A properties in active construction to meet the growing demand of the life science industry.


ISPE SD 2-25-21 Webinar Info Graphic

DETAIL

REGISTER